Q-omics provides the consensus-scored RPS19P7 profile across patient tissues and cancer cell-line models. RPS19P7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS19P7 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPS19P7 RNA expression shows 12,860 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, COAD, and DLBC as cancer lineages where RPS19P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS19P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS19P7 survival associations across molecular data types. RPS19P7 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS19P7 RNA expression–survival associations across cancer types. High RPS19P7 expression shows unfavorable associations in ACC, LIHC and KIRP, but favorable associations in KIRC, COAD and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS19P7 RNA expression.
This table summarizes RPS19P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS19P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS19P7 shows higher tumor expression in COAD, KIRC, STAD, LUSC, LIHC and ESCA. The COAD box plot shows higher RPS19P7 RNA expression in tumor versus normal tissue (log2 FC = +1.751, t-test p < 0.001).
This table shows molecular features associated with RPS19P7 in patient tissues and cancer cell lines. In patient samples, RPS19P7 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
